托伐普坦治疗快速进展型常染色体显性多囊肾病实用指南
本文针对托伐普坦治疗快速进展型常染色体显性多囊肾病(ADPKD)的临床实践问题,提供了从诊断确认、患者选择、用药前评估到用药后监测的实用指导。基于已发表证据和临床试验经验,重点阐述了水钠排泄相关并发症的预防和肝酶升高的管理,以确保治疗安全有效。
要点
- 用药前需确认ADPKD诊断并识别快速进展风险。
- 治疗中需教育患者水钠排泄反应并预防相关并发症。
- 定期监测肝酶,及时评估和管理肝酶升高。
核心结论
- 托伐普坦是FDA批准的首个用于延缓快速进展型ADPKD成人肾功能下降的药物,需按实用步骤规范使用。
研究设计与样本
- 综述性实践指南,基于已发表证据及托伐普坦在ADPKD随机临床试验和开放标签扩展研究中的集体经验。
主要发现
- 提出了用药前后需考虑的步骤,包括诊断确认、快速进展识别、基础肾脏保护措施、患者咨询、排除标准、水钠排泄教育、起始与滴定优化、并发症预防、肝酶监测及疗效评估。
临床怎么用
- 肾内科医生应遵循所述步骤,在处方托伐普坦前后系统评估和管理患者,确保治疗安全有效。
局限性
- 推荐基于已发表证据和临床试验经验,非系统评价或新研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. These steps include confirmation of diagnosis; identification of rapidly progressive disease; implementation of basic renal protective measures; counseling of patients on potential benefits and harms; exclusions to use; education of patients on aquaresis and its expected consequences; initiation, titration, and optimization of tolvaptan treatment; prevention of aquaresis-related complications; evaluation and management of liver enzyme elevations; and monitoring of treatment efficacy. Our recommendations are made on the basis of published evidence and our collective experiences during the randomized, clinical trials and open-label extension studies of tolvaptan in ADPKD.
引用
- Chebib FT, Perrone RD, Chapman AB, et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018. PMID: 30228150. doi:10.1681/ASN.2018060590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。